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Retinopathies in human and animal models have shown to occur through loss of peri-
cytes resulting in edema formation, excessive immature retinal angiogenesis, and neuronal
apoptosis eventually leading to blindness. In recent years, the concept of regenerating ter-
minally differentiated organs with a cell-based therapy has evolved.The cells used in these
approaches are diverse and include tissue-specific endogenous stem cells, endothelial
progenitor (EPC), embryonic stem cells, induced pluripotent stem cells (iPSC) and mes-
enchymal stem cells (MSC). Recently, MSC derived from the stromal fraction of adipose
tissue have been shown to possess pluripotent differentiation potential in vitro. These adi-
pose stromal cells (ASC) have been differentiated in a number of laboratories to osteogenic,
myogenic, vascular, and adipocytic cell phenotypes. In vivo, ASC have been shown to have
functional and phenotypic overlap with pericytes lining microvessels in adipose tissues.
Furthermore, these cells either in paracrine mode or physical proximity with endothelial
cells, promoted angiogenesis, improved ischemia–reperfusion, protected from myocardial
infarction, and were neuroprotective. Owing to the easy isolation procedure and abundant
supply, fat-derived ASC are a more preferred source of autologous mesenchymal cells
compared to bone marrow MSC. In this review, we present evidence that these readily
available ASC from minimally invasive liposuction will facilitate translation of ASC research
into patients with retinal diseases in the near future.
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INTRODUCTION
Diabetic retinopathy (DR) is the most common vascular compli-
cation in patients with long-standing diabetes, and is the leading
cause of blindness in working-age adults. The estimated preva-
lence in USA is 5.4% (~7 million) (1). Future projections suggest
that DR will increase as a public health problem, with increase in
aged population and increasing prevalence of diabetes over time.
In the early stages of DR, one notices clinically significant mac-
ular edema (ME). This presumably develops concomitant with
pericyte loss, basement membrane thickening, and endothelial
dysfunction involving loss of its barrier integrity. Subsequent clo-
sure of retinal capillaries results in retinal ischemia and aberrant
growth factor secretion, neovascular formation, characteristic of
proliferative DR (PDR). Current strategies for the therapeutic
management of DR include laser photocoagulation, intravitreal
triamcinolone (IVT), and intravitreal injection of VEGF neutral-
izing agents (e.g., Avastin). Patients undergoing laser treatment
continue to remain at risk for new bleeding episode requiring
multiple laser treatments. Triamcinolone, which is relatively more
successful in suppressing ME, requires intravitreal administra-
tion. However, this procedure is fraught not only with side effects
but also adverse reactions such as sub-capsular cataract, onset of
steroid-induced glaucoma, and potential for endophthalmitis. Use
of intravitreal Avastin against ME or PDR has not been successful
with the effect lasting for only a short period.
ROLE FOR PERICYTES IN DR
Diabetic retinopathy develops as sustained metabolic dysregula-
tion and inflicts progressive damage to the retinal microvascula-
ture, increasing vascular permeability, and, in advance stages, leads
to the aberrant proliferation of vascular endothelial cells (2). As
the global level of diabetes is increasing at a rapid rate, there is
necessity to understand the molecular mechanisms responsible
for diabetes-induced complications, specifically retinal pathology.
One of the well-accepted theories of potential development of DR
is due to loss of pericytes (3). Pericytes are specialized perivas-
cular cells, derived from the vascular smooth muscle lineage,
that reside in close contact with endothelial cells within a com-
mon basement membrane. Although pericytes share many mark-
ers with smooth muscle cells (SMC), they can be distinguished
from SMC by decreased SMC-alpha-actin and increased platelet-
derived growth factor (PDGF)-receptor (PDGFR) expression (3).
They are believed to provide a nourishing, anti-inflammatory and
anti-angiogenic environment for endothelial cells. The formation
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of the blood–retinal barrier (BRB) is dependent on the interaction
of the vascular endothelial cells with both glial cells and pericytes.
Endothelial cells recruit pericytes through expression of PDGF,
and pericyte activation, in turn, modulates blood vessel homeosta-
sis and endothelial cell growth. The importance of PDGF signaling
has been demonstrated with a loss of function experiments of
PDGF signaling, resulting in lower retinal pericytes and subse-
quent vascular degeneration and increased vascular angiogenesis
(4). More recently, a new protein kinase C-δ (PKC-δ)-dependent
signaling pathway in pericytes via SHP-1 protein has been shown as
a mechanism of pericyte apoptosis by downregulating PDGF sig-
naling (5). Angiopoietin-1 (Ang-1) is one pericyte produced factor
believed to be essential for these stabilizing functions (6). Ang-1
has been demonstrated to increase survival, anti-inflammatory
properties, and barrier function of endothelial cells and absence
of Ang-1 leads to increased expression of Ang-2 (7). Ang-2 is
an antagonist of Ang-1, which can interfere with tie-2 receptor
activation and signaling, leading to decreased endothelial and
pericyte cell survival but also to increased endothelial cell acti-
vation (8, 9). Recently, the anti-inflammatory activity of Ang-1
has been explained by decreasing the responsiveness of endothe-
lial cell to TNFα (10). Furthermore, inflammatory cytokines such
as TNF has been linked to pericyte apoptosis and inhibition of
TNF reduced pericyte ghost formation with decreased acellular
capillary formation caused by type 1 and type 2 diabetes (11).
Accumulating evidence points to the fact that exposure of retinal
pericytes to high glucose results in increased pro-apoptotic Bim
expression and oxidative stress leading to reduced migration with
a significant impact on their rate of apoptosis (12). These find-
ings implicate pericytes as potential mediators of DR and outline
potential strategies for targeted therapies based on their regulation.
STEM CELLS AND OCCULAR ANGIOGENESIS
Loss of pericytes and endothelial cells was central to the patho-
genesis of DR (2). If cell loss is solely responsible for disease, a
definitive treatment would involve cell replacement. Stem cells
offer the promise of regenerating tissue in organs such as the eye,
brain, and heart, damaged by trauma or disease. Over the past
decade, literature has emerged that strongly supports the poten-
tial for exploiting stem/progenitor cells to maintain, and support
abnormal tissue in several diseases, which perhaps can also be
extrapolated to retinal diseases. About four basic populations of
cells are known as of today (13) that contain progenitor cells
which, under appropriate circumstances, may have therapeutic
application in the treatment of retinal disease: (1) retinal stem
cells that can give rise to photoreceptors and other retinal neu-
rons; (2) Mueller/glial stem cells that can differentiate into retinal
glia and/or neurons; (3) retinal pigment epithelial (RPE) stem
cells that can not only serve to replace diseased RPE but perhaps
can also be stimulated to differentiate into photoreceptors; and
(4) endothelial, myeloid progenitor cells, adult stem cells, induced
pluripotent stem cells (iPSC) that can contribute to the retinal
vasculature and exert vasculo- and neurotrophic rescue effects
(Table 1). Research aimed at re-engineering stem cells to develop
into vasculature is of great benefit to the DR patients. One of
the early publications from Friedlander’s laboratory reported that
Lin− hematopoietic stem cells (HSCs) from bone marrow injected
Table 1 | Stem cells that are implicated in the cell-based therapy for
retinal diseases.
Source Stem/progenitor markers Reference
Hematopoietic stem cells
(HSC)
CD44hi/CD11a+/CD11b+/
Ly6G/C+/F4/80+/CD14, cKit+
(15)
Endothelial progenitor (EPC) CD34+ (18)
Embryonic stem cells CD31+/CD146+ (70, 71)
Induced pluripotent stem
cells (iPSC)
CD31+/CD146+ (70, 72)
Umbilical cord blood
(UCB)-derived myeloid
progenitor cells
CD14+ (73)
Mesenchymal stem cells
(MSC)
CD31−/CD34−/CD44+/
CD45−/CD73+/CD90+/
CD105+/CD140b+
(43, 45)
A limited compilation of stem cells that are implicated in retinal diseases with
specific emphasis on retinopathy where applicable.
directly into the mouse eye targeted activated astrocytes, and par-
ticipate in normal developmental angiogenesis in neonatal mice or
injury-induced neovascularization in the adult (14, 15). Interest-
ingly, these HSCs, transfected with a plasmid encoding a secreted
anti-angiogenic peptide, T2-tryptophanyl-tRNA synthetase, pro-
foundly inhibited retinal angiogenesis suggesting that engineered
to produce a secreted peptide that can inhibit further proliferation
of new vessels and perhaps to stabilize (mature) vessels, provides
the hope that cell-based therapy may be useful in the inhibition
of proliferative retinopathies (14). Lineage identification in these
HSC suggested that CD44hi cells via a HIF1α-mediated mecha-
nism suggested to play a role in oxygen-induced retinopathy model
(OIR) (15). It is noteworthy to mention that in this study, no label-
ing was present with antibodies against CD31 or NG2 indicating
that these cells are unlikely to be differentiating into endothelial
cells or pericytes but rather gave neurotrophic support to form
neovascularization (13). In contrary, another model of adult neo-
vascularization using organ-specific VEGF expression, Grunewald
et al. showed that bone marrow-derived myeloid cells targeted
the site of VEGF expression in an SDF-1-mediated mechanism
and promoted vessel growth after assuming perivascular local-
ization (16). Along the same lines, another recent study demon-
strated that SDF-1 released from platelets mobilized and recruited
CD11b-expressing myeloid cells to sites of neovascularization in a
model of hind-limb ischemia for new vessel growth (17). Alternate
approaches included, insulin-like growth factor binding protein-3
(IGFBP-3) increased differentiation of GFP(+) HSCs into peri-
cytes and astrocytes thereby increasing vascular ensheathment of
pericytes and decreasing apoptosis of pericytes and retinal neu-
rons in the OIR model. Among cell-based approaches intended
to address DR, in addition to myeloid progenitor cells, intrav-
itreal injection of CD34+ endothelial cells (18) have been very
successful to prevent vascular regression and protect neurons in
genetic mouse models of retinal degeneration. However, to date,
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the identity and cell surface markers expressed by these cells remain
incompletely defined (19). Diabetes causes metabolic and physi-
ologic abnormalities in the retina, and these changes suggest a
role for inflammation, altered cytokine expression (11, 20–28),
dysfunction, and even degeneration of some neuronal cells (29,
30). These findings call for potential targeted cell therapies that
display anti-inflammatory and anti-apoptotic behavior for sub-
sequent vascular stabilization and neuronal repair early in DR
rather than at later stages of vascular angiogenesis. There is also
poor understanding of signaling events in these transplanted stem
cells. A comprehensive understanding of key cellular and molec-
ular pathways is urgently needed so as to optimize their ability to
survive in the pathological in vivo diabetic microenvironment.
It is imperative that for treatment of diabetic vessel damage,
transplanted cells be capable of withstanding the in vivo diabetic
microenvironment (31).
Recently, we and others have proposed the use of mesenchymal
cells as an alternate approach to cell therapies for DR. Mesenchy-
mal stem cells (MSC) that have been obtained from bone marrow,
peripheral blood, cord blood as well as stem cells derived from
other sources such as adipose tissue is expected to have an impact
on cell therapy in eye diseases. For example, adult bone marrow
MSC positive for CD90 have been shown to partially differentiate
into photoreceptors in vitro and in vivo (32) and local, but not sys-
temic, transplantation of MSC is neuroprotective in a rat glaucoma
model (33). Recently, adipose stromal cells (ASC) transplanted
into diseased corneas preserved transparency as well as differen-
tiated into functional keratocytes suggesting that these cells could
be used as a source for stromal regeneration and repopulation in
diseased corneas (34). Differentiation potential of ASC into the
neuroectodermal lineage, yielding cells with phenotypic charac-
teristics of RPE cells also has been recently documented, which is
expected to alleviate the non-exudative form of age-related macu-
lar degeneration (ARMD) characterized by a progressive decay
of RPE cells at the posterior pole of the eye (35). In sodium
iodate mediated acute retinal damage model, engineered MSC
that overexpress neurotrophin-4 were found safe and very effective
intravitreally suggesting engineered MSC may represent a useful
strategy for treatment of different forms of retinopathies in the
future (36).
THE PLASTICITY OF PERICYTES IN ADIPOSE TISSUE
Adipose stromal cells are multipotential mesenchymal progenitor
cells that are readily induced to undergo adipogenic differentia-
tion, and have been recently demonstrated to have functional and
phenotypic overlap with pericytes lining microvessels in adipose
tissues (37, 38). Pericytes and ASC are both of mesenchymal origin
and ASC can be differentiated into skeletal muscle cells,osteoblasts,
chondrocytes, and adipocytes (39–42). Recent evidence suggests
that human ASC and pericytes express identical surface markers
including NG2, PDGFR α and β, and N-cadherin (37). Human
adipose tissue sections revealed that ASC markers including both
CD34 and CD140b were restricted to perivascular cells and formed
robust functional vascular networks in vivo by cooperation of ASC
with endothelial cells (37). The fact that ASC share functional
properties as well as phenotypic markers with perivascular peri-
cytes, makes these cells an attractive option to treat DR from the
perspective of vascular stabilization and the restitution of pericyte
dropout (Figure 1).
An elegant study by Yates group employed intravitreal injec-
tion of differentiated pericytes from human ASC via TGF-β1
treatment, could integrate into the retinal vasculature in two
non-diabetic models, OIR and Akimba model on the abluminal
locations around retinal capillaries, which is a defining character-
istic of pericytes (43). Because the neovascular changes observed
in the Akimba mouse are not due to long-term hyperglycemia,
as in human DR (44), we developed a streptozotocin (STZ)-
induced chronic hyperglycemia DR model and for the first time
demonstrated that intravitreal injection of ASC in a chronic dia-
betes model pair with host vasculature in a perivascular location,
possibly suggesting pericyte replacement (45). Interestingly, ASC
requires a minimum of 3–6 weeks to pair with host vasculature
to wrap around blood capillaries to stabilize vasculature in vivo
as is also true with hind-limb ischemia models (46). Although
more studies are warranted, the ability to provide such perivascu-
lar cells in the early stages of disease would represent a significant
advancement in our understanding of the role of ASC cell therapy
in DR.
Adipose stromal cells have a remarkable property to self-
assemble into vascular structures in contact co-cultures with a
number of endothelial cell types including retinal endothelial cells
(45, 47). This property is not unique to ASC but also bone marrow
FIGURE 1 | Hypothetical model of regenerative cell therapy with
adipose stromal cells (ASC) in retinopathy. Under
normoglycemic/non-pathological conditions (NG), intact retinal endothelium
protected by pericytes is relatively impermeable; but becomes leaky under
hyperglycemic stress (HG), in conjunction with downregulation of several
proteins including Angiopoietin-1 (Ang-1), a characteristic feature observed
in retinopathy. Because ASC and pericytes share phenotypic characteristics,
it is hypothesized that cell therapy involving intravitreal injection of
autologous ASC will ameliorate such loss of pericytes and consequent
vascular permeability. Because ASC produce cytoprotective factors, it is
anticipated that they will also promote vascular and neurodegeneration
repair in retinopathy.
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MSC have been shown to form networks with HUVEC (48). It is
quite interesting to note that MSC take up perivascular position
while the endothelial cells form angiogenic tube like structures in
this 2D coculture. These studies shed new light on the vasculo-
genic potential of ASC depends on interaction with endothelial
cells involving contact and likely bi-directional interaction, result-
ing in modulated secretion of cytokines and matrix proteins that
are essential for stabilized vessels. In support of this, recently ASC
were shown to secrete Ang-1 in a time-dependent manner, espe-
cially when cultured in medium containing growth factors for
vascular endothelial cells and promoted reendothelialization (49).
Early data from our laboratory suggest that these vessel stabilizing
properties of ASC are unaltered in hyperglycemic environment
taking one step forward to suggest that ASC are pre-programed
to sustain the hostile diabetic environment. More studies are war-
ranted if ASC produced Ang-1 or other proteins play a vital role
in the vascular stabilization and rescue from retinal injury.
MESENCHYMAL CELLS AND NEUROPROTECTION IN DR
Apart from their role as perivascular cells, ASC are also known to
produce a variety of angiogenic and anti-apoptotic factors (50),
which in turn may promote dual beneficial effects addressing both
capillary and neurodegeneration (Figure 1). We and others have
shown that ASC act both in a paracrine manner as well as by direct
physical interaction with endothelial cells to modulate angiogen-
esis (51), reduce skeletal muscle ischemia, and tissue loss (50),
limit myocardial infarction (52), promote skin repair (53), and
provide neuroprotective function against serum and potassium
deprivation-induced cerebellar granule neuronal apoptosis (54,
55). These seminal studies have led to the concept that the adi-
pose tissue may provide a novel autologous source of putative
stem cells with significant potential for tissue repair and rescue
from diabetic injury. The latter study establishes a mechanistic
basis supporting the therapeutic application of ASC for neurolog-
ical disorders, specifically through paracrine support provided by
trophic factor secretion, which may be of paramount importance
in regeneration of photoreceptors/astrocytes in retinal injury. To
this end, intravenous injection of ASC in the STZ-induced DR rat
model demonstrated an improvement in blood glucose levels as
well as BRB integrity, with few donor cells differentiated into pho-
toreceptor or astrocytes-like cells (56). Based on the fact that the
diabetes itself is largely ameliorated with the intravenous injection
of ASC via improved glucose tolerance, preserved beta cell mass,
and increased beta cell proliferation in STZ-treated NOD-SCID
mice (57), it is not clear if the improvement of BRB integrity is
a direct result of ASC replacement of cells in the retina or due to
the general decrease in blood glucose. Although the mechanisms
are unclear, based on our studies performed with trophic factors
in both STZ-induced DR and retinal ischemia–reperfusion (I/R)
injury models, local intravitreal injection of trophic factors from
ASC support the speculation that the paracrine trophic factors
released by ASC play key roles by both stabilizing vasculature, and
in protecting retinal cells from diabetic damage. In favor of this
hypothesis, recently ASC have been shown to secrete physiologi-
cally relevant levels of several anti-apoptotic, anti-inflammatory,
and chemotactic proteins (such as tumor necrosis factor-inducible
gene 6, TSG6; stanniocalcin-1, STC-1; Rantes, CCL5; stem cell
factor, SCF (37), tissue inhibitor of metalloproteinase1, TIMP-1
(57), which have been shown to mediate some of the beneficial
effects of MSC (57–59). Future studies with detailed molecular
approaches are needed to specifically identify the use of these
specific proteins in DR.
CLINICAL TRIALS IN DR
At the time of this review, there are over 200 open clinical trials
using MSC with diseases ranging from Crohn’s disease to car-
diomyopathy to rheumatoid arthritis. There are only two clinical
trials that directly address DR using bone marrow-derived MSC
(NCT01518842) and bone marrow-derived CD34+ cells (a pilot
clinical trial of the feasibility and safety of intravitreal autologous
adult bone marrow stem cells in treating eyes with vision loss
from retinopathy; NCT01736059). While MSC are not a preferred
choice as of today, early 2012, FDA approved a first of its kind clin-
ical trial (A phase I/II, open-label, multi-center, prospective study
to determine the safety and tolerability of sub-retinal transplan-
tation of human embryonic stem cell-derived retinal pigmented
epithelial (MA09-hRPE) cells in patients with advanced dry AMD;
NCT01344993) for the use of embryonic stem cells (ES) for the
treatment of AMD, an age-related retinal disease with loss of cen-
tral vision. It was reported that two patients who received stem
cells showed improvement in their vision and it is encouraging
that during the observation period of 4 months neither patient
lost vision (60). However, ES cells are controversial and their use
is tainted by ethical issues. Similarly, iPSC cells are being tested
in Japan in a clinical study (61) and one can hope it will show
enough efficacy to encourage formal clinical trials, however, as
with ES, iPSC cells are also under scrutiny and the use of four
genes to make a stem cell and their long-term efficacy is contro-
versial. Obviously, safety and efficacy is one of the main key point
for FDA approval, there are studies aiming at the very safety and
efficacy of MSC in newly diagnosed Type 1 diabetic patients is
ongoing, which will inform us on how these cells behave in vivo
in long-term (Safety and efficacy of mesenchymal stem cells in
newly diagnosed type 1 diabetic patients; NCT01322789). In par-
ticular, ASC are currently being investigated in clinical trials in
several fields (chronic inflammation, ischemic diseases, etc.) and
the emerging results of these trials will provide a great deal of
data concerning the safety of ASC use (62). Unlike other stem cells
such as iPSC, which needs extensive manipulation of cell arma-
mentarium, ASC need few, if any, such manipulations making its
use more advantageous over other cell types. Unfortunately, in
countries like Mexico and Europe ASC are already being used in
clinical treatment of DR, compromising the safety of patients as
well as hindering our ability to perform rigorous clinical studies in
US. We as a scientific community must perform rigorous scientific
studies to ensure their safety without compromising the efficacy
before offering clinical trials in the United States.
CHALLENGES AND FUTURE DIRECTIONS OF CELL THERAPIES
IN DR
There are multiple challenges for cell therapies with MSC in DR.
(1) Pericytes are mesenchymal in origin and express multiple
cell surface markers (CD140b, CD146, NG2, SMA, Desmin)
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depending upon the tissue or the subpopulation derived from
the tissues. This brings enormous heterogeneity in MSC,
which may contribute to different outcomes in DR.
(2) The heterogeneity in MSC may mandate us to purify and
enrich a subpopulation to define differentiation with speci-
ficity to pericyte. Emerging data from pericyte progenitors
from MSC engraft preferentially at perivascular location (63,
64). Furthermore, precisely characterized pericytes are less
likely to generate unwanted cell type making it an ideal
candidate for FDA approval.
(3) Route of injection may be of concern. In line with other cell
therapies approved for DR, we chose to do intravitreal injec-
tions of ASC as it benefits from direct delivery of these cells
into the eye close to the damaged retinal vasculature. Further-
more, unlike for endothelial progenitor cells, pericytes from
abluminal side may yield quick results. However, we would
need to evaluate the relative merit of intravenous, intraor-
bital, or sub-retinal injection of MSC in future studies as these
routes are routinely used in clinical ophthalmology.
(4) Well-characterized vasoregenerative cells that are ready for
clinical application for human use is necessary. This may
include a combination of MSC and CD34+ cells or other
endothelial progenitor cells as one cell type alone may not
help develop patented vessels. To this end, we have recently
shown that ASC markedly enhanced retinal endothelial cell
survival under hyperglycemic conditions; and in contact co-
cultures, ASC formed robust vascular networks with retinal
endothelial cells, much as with cord blood endothelial cells
(45, 47). Emerging data indicate that direct cell–cell contact
between MSC and endothelial cells may induce pericyte phe-
notype in MSC with marked expression of SMA as well as
other pericyte markers such as CD146 (47, 65).
(5) One of the challenges for MSC transplantation therapy for DR
is the secretion of angiogenic growth factors produced by ASC,
such as VEGF and HGF (50), which may adversely affect retina
for proliferative changes. Although MSC have been shown to
produce paracrine trophic factors that may modulate between
a pro-angiogenic to anti-angiogenic state depending upon
the microenvironment (66–69), a careful regulation of ASC
differentiation may be necessary.
(6) Another general challenge of stem cell-based treatments is
the relative rudimentary characterization of derived cells.
Most studies rely on a rather limited survey of extracellu-
lar markers rather than functional evaluation of the derived
cells.
CONCLUSION
Mesenchymal cells in particular ASC are preferred choices of cell
therapy in ischemic and diabetic diseases. The ready availabil-
ity of large numbers of autologous cells with the capabilities of
facilitating repair of vascular and neurogenic tissues would be
highly significant clinically for patients with retinal diseases such
as AMD, DR, and retinitis pigmentosa. The resulting therapies
would involve a minimally invasive procedure such as liposuction
to harvest adipose tissue, followed by any processing required to
obtain an appropriately defined and functionally consistent pop-
ulation of cells with the desired characteristics. Because of the
extremely large numbers of cells available from such harvests, this
processing might simply include isolation/separation steps in the
absence of any need for expansion; or conversely might include
culturing in the presence of either specific media, growth fac-
tors, or even genetic material that preferentially activate/suppress
specific signaling events involved in competing differentiation
pathways for the purpose of directing subsequent cellular behav-
ior. Studies undertaken in rodent models will help determine if
stem cells isolated from the adipose tissue can be used as vehicles
for long-term, sustained delivery of therapeutic agents to eye tis-
sues, or replace the diseased tissue with stem cells that can take
their function. By evaluating this approach in the rodent model,
we will be in a better position to determine whether such an
approach should be tested in humans with a variety of retinal
diseases.
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